Alto Neuroscience (ANRO) Long-Term Debt Repayments (2025)
Alto Neuroscience (ANRO) reported Long-Term Debt Repayments of $10.2 million for Q1 2025.
Alto Neuroscience (ANRO) Long-Term Debt Repayments (2025) Analysis & Trends
Alto Neuroscience (ANRO) has 1 years of Long-Term Debt Repayments data on file, last reported at $10.2 million in Q1 2025.
- For the quarter ending Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $10.2 million; the trailing twelve-month figure through Dec 2025 stood at $10.2 million (changed N/A YoY), and the FY2025 full-year result was $10.2 million, changed N/A from the prior year.
- Long-Term Debt Repayments steadied at $10.2 million in Q1 2025.
- In the past five years, Long-Term Debt Repayments ranged from a high of $10.2 million in Q1 2025 to a low of $10.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 7.64 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alto Neuroscience | 869.36 Mn | 869.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 10.21 Mn |
| Mar 31, 2025 | 10.21 Mn |